Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in moderate-to-severe COPD with type 2 inflammation
NL-OMON54320Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB), sponsored by Sanofi. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NL-OMON54320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54320.